What Ravicti Treats: Main Uses and Benefits

Glycerol phenylbutyrate is considered relevant for the management of Urea Cycle Disorders (UCDs), conditions associated with systemic imbalance and the accumulation of waste nitrogen. This therapy is generally applied in both pediatric patients including infants and adults when diet and amino acid supplementation are not sufficient to support metabolic control, and is applied in clinical settings that involve chronic systemic burden.

The medicine is relevant in conditions involving recurrent or episodic manifestations, including specific UCD deficiencies such as Ornithine Transcarbamylase Deficiency (OTCD), Argininosuccinate Synthetase Deficiency (ASSD), and Carbamoyl Phosphate Synthetase 1 Deficiency (CPS1D). The medication is applied in addressing symptoms related to systemic imbalance and helps manage nitrogen accumulation, which assists with managing symptoms that create noticeable physiological strain. This sustained control over systemic imbalance is relevant for easing the overall burden of symptoms that interfere with daily functioning and contributes to easing the overall symptom load during episodes of heightened discomfort. It is commonly used as an adjunct to a low-protein diet, assisting with metabolic support.

Eligibility Map: Who Can and Cannot Use Ravicti — Official Regulatory Information

The use of Ravicti (glycerol phenylbutyrate) is governed by strict regulatory rules defining the authorized patient population.

Connection to the overall eligibility profile:

Regulatory documents establish that the medicine is limited to the chronic management of UCDs and is contraindicated in specific groups, including infants under two months. Eligibility is further constrained by physiological factors: patients with liver or kidney impairment, as well as those with pancreatic insufficiency, require conditional use and close monitoring.

Glycerol phenylbutyrate's official interaction profile is characterized by its effect on key metabolic pathways and the potential for reinforcing hyperammonemia risk. This information is derived exclusively from regulatory documents.

Interactions Affecting Other Medicines (CYP3A4 Induction)

Glycerol phenylbutyrate is officially identified as a weak inducer of the metabolic enzyme CYP3A4. This action may decrease the systemic exposure of other medicines that are highly dependent on this enzyme for clearance. Specific examples of drugs with a narrow therapeutic index listed in regulatory documents include alfentanil, quinidine, and cyclosporine. The systemic exposure to midazolam is also noted to be decreased upon co-administration.

Interactions Affecting Ammonia Levels

Co-administration with certain medicinal products requires close clinical monitoring due to the potential for an increase in plasma ammonia levels. These agents include corticosteroids, valproic acid, and haloperidol. Corticosteroids may increase ammonia by promoting protein breakdown, while valproic acid and haloperidol are noted to induce hyperammonemia.

Metabolite and Organ Impairment Notes

The medicine Probenecid may affect the renal excretion of the active metabolites phenylacetylglutamine and phenylacetate. Furthermore, in patients with underlying hepatic or renal impairment, caution is advised, and close monitoring of ammonia levels is required during co-administration of interacting medicines due to potential changes in drug metabolism or elimination. There are no mandatory timing separation rules for any co-administered products.

How Ravicti Works

Establishing the Nitrogen Scavenging Mechanism

This medication is introduced as an inactive compound (a prodrug) that is converted into the active scavenger molecule, phenylacetate, after being metabolized by the body's digestive and hepatic systems. This metabolic process generates the necessary chemical agent to engage the waste removal pathway, which results in the delivery of the active agent for systemic action.

Engaging the Alternative Nitrogen Disposal Pathway

The active molecule selectively binds to the amino acid glutamine, which contains two atoms of waste nitrogen. This enzymatic conjugation reaction effectively traps the nitrogen load, creating a new, neutral waste product, phenylacetylglutamine . The action establishes an alternate mechanism for nitrogen removal, independent of the urea cycle.

Achieving Sustained Nitrogen Clearance

The resulting compound is water-soluble and is transported to the kidneys for elimination via urine excretion. This continuous removal mechanism facilitates the steady elimination of precursor nitrogen, resulting in a reduction of nitrogenous waste in the systemic circulation.

Administration Route and Timing

Ravicti is an oral liquid solution administered for chronic management; it is not indicated for the treatment of acute hyperammonemia. The medication is taken by mouth using an oral syringe or dosing cup, but it can also be administered through a nasogastric (NG) or gastrostomy (G) tube.

Administration must occur with meals or feedings to synchronize with daily protein intake. The total daily dosage must be split into multiple equally divided doses. Patients aged two years and older receive three equally divided doses, each rounded up to the nearest 0.5 mL. Patients under two years receive three or more equally divided doses, rounded up to the nearest 0.1 mL.

Official Dosing and Preparation

The total daily dose is individualized based on the patient's Body Surface Area (BSA), within a recommended range of 4.5 to 11.2 mL/ m^2/ day. The maximum total daily dosage must not exceed 17.5 mL. For specific populations, such as those with moderate-to-severe hepatic impairment, the starting dose is the lower end of the recommended range.

The oral liquid must be used concomitantly with dietary protein restriction. The solution should not be added to a large volume of liquid. It may be mixed with a small amount of soft food (e.g., applesauce or squash puree), provided the mixture is used within two hours. A missed dose should be taken as soon as recognized, unless the next dose is within two hours (adults) or thirty minutes (children), in which case the missed dose should be omitted.

Research evidence / Overview of studies for Ravicti

The research base for glycerol phenylbutyrate involves studies exploring how the drug is observed in the context of chronic metabolic management for individuals with Urea Cycle Disorders (UCDs) who require ongoing intervention beyond diet alone. These conditions are characterized by outcomes related to systemic imbalance.

Evidence for the Chronic Management of Urea Cycle Disorders (UCDs)

The core evidence includes a Phase 3, short-term, randomized, double-blind, active-controlled, crossover trial in adult patients. This design was used to compare the short-term use of glycerol phenylbutyrate against an existing nitrogen-scavenging agent. Researchers in these studies monitored key measures, primarily ammonia homeostasis, measured through the 24-hour plasma ammonia exposure. The comparative study evaluated whether metabolic biomarkers remained within a predetermined statistical range when compared to the active comparator. The research monitored specific metabolic and clinical event measures, such as the frequency of hyperammonemic crises (HACs).

Long-Term Studies and Extended Follow-Up

Following the initial comparative trials, patients often transitioned into open-label, uncontrolled long-term extension studies. This research was designed to examine the metabolic patterns observed in the short term and monitored them over a longer duration, with some follow-up periods lasting up to 24 months. Studies observed responses and collected data on annualized rates of HACs during these sustained periods of treatment. However, the evidence for long-term clinical outcomes relies mainly on these uncontrolled extension studies, and long-term effects are not fully established based on randomized data alone.

What Remains Unclear or Under Research

The majority of the evidence comes from patients who were already stabilized on a similar treatment before switching. Therefore, comparative evidence is lacking for patients initiating chronic treatment for the first time. Regulators also noted that the clinical program did not establish the use of the drug in all types of UCDs; specifically, the evidence is limited for its application in N-acetylglutamate synthase (NAGS) deficiency. Overall, the evidence quality varies across studies, and data for certain groups, such as children aged 2 months to less than 2 years, remain insufficient.

The storage and disposal of Ravicti oral liquid are defined by specific regulatory requirements to maintain product stability and ensure safety.

Storage and Stability

The medicine must be stored in its original container at controlled room temperature, specifically between 68 F to 77 F (20 C to 25 C). The bottle cap must be kept tightly closed.

Critically, the product must be protected from water, as contact causes degradation; if the liquid appears cloudy, it must not be used. After the bottle is first opened, the contents must be discarded after 14 days (or 28 days, depending on region), regardless of the remaining volume.

Handling and Disposal

The product must be kept out of the sight and reach of children. The oral syringe used for administration must not be rinsed between daily doses (due to the water degradation risk) and must be discarded after the last dose of each day. Unused product and waste materials must be disposed of in accordance with national requirements.